In the last decade, new oral anticoagulant agents with a direct inhibition of specific clotting factors (DOACs) have been claimed as first-choice therapy for the prevention of cardioembolic events in patients with atrial fibrillation and for the treatment of venous thromboembolism (VTE) thanks to improved safety and ease of use in comparison to vitamin K antagonists (VKAs) [1,2].
